15:58 , Nov 16, 2018 |  BC Week In Review  |  Financial News

Swiss cancer play Amal eyes clinic following €21.2M tranche

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the total amount raised in the round to €29 million...
10:56 , Nov 12, 2018 |  BC Extra  |  Financial News

Swiss cancer play Amal eyes clinic following €21.2M tranche

Cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) closed the second and final tranche of its series B round at €21.2 million ($24 million), bringing the total amount raised in the round to €29 million...
17:33 , Mar 2, 2018 |  BC Week In Review  |  Financial News

BioMedPartners closes third fund at CHF100M

BioMedPartners (Basel, Switzerland) closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany...
18:11 , Mar 1, 2018 |  BC Extra  |  Financial News

BioMedPartners closes third fund

BioMedPartners closed its BioMedInvest III fund at CHF100 million ($107 million). The firm plans to invest the fund in 12-15 private early to mid-stage pharmaceutical, medical device and diagnostics companies in Switzerland, Germany and neighboring...
16:17 , Sep 8, 2017 |  BC Week In Review  |  Financial News

Amal raises $9.5M in first close of series B round

On Sept. 5, cancer vaccine company Amal Therapeutics S.A. (Geneva, Switzerland) raised €8 million ($9.5 million) in the first close of a series B round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Financial News

Amal Therapeutics completes venture financing

Amal Therapeutics S.A. , Geneva, Switzerland   Business: Cancer   Date completed: 2016-03-30   Type: Venture financing   Raised: CHF3 million ($3.1 million)   Investors: Boehringer Ingelheim Venture Fund; VI Partners; High-Tech Gruenderfonds  ...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Company News

University of Minnesota, Amal Therapeutics deal

The university granted Amal exclusive rights to a patent covering the use of a peptide with immunostimulatory properties when used as an adjuvant for cancer vaccines. The partners did not respond to inquiries. University of...
07:00 , Jun 23, 2014 |  BioCentury  |  Emerging Company Profile

Amal: Party of two

Amal Therapeutics S.A. is developing a platform of recombinant cancer vaccines that may induce a more potent and durable response than earlier vaccines by activating two different cell types important in antitumor immunity and by...